TECH Q1 Deep Dive: Biotech Weakness and Order Timing Drive Top-Line Miss

Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.5% year on year to $311.4 million. Its non-GAAP profit of $0.53 per share was in line with analysts’ consensus estimates.

Is now the time to buy TECH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our surprise,” as early-stage funding remained weak and order activity lagged expectations.

Looking ahead, management’s guidance is shaped by cautious optimism regarding a potential recovery in biotech spending and ongoing stabilization in academic markets. CFO James Hippel noted that, while indicators such as strong funding and increased customer engagement are encouraging, the translation of funding into actual orders typically lags by two to three quarters. Kelderman emphasized, “We are somewhat careful. And I think that’s the right thing to do,” reflecting a prudent approach as Bio-Techne awaits more consistent improvement in its key end markets.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to a combination of external demand headwinds in biotech, positive momentum among large pharma clients, and product-specific timing impacts.

• Emerging biotech softness: The weak performance in emerging biotech was a significant drag, with management noting a high single-digit decline due to sluggish early-stage funding and delayed order conversion. This weakness offset gains from other segments.

• Order timing impact: Two major cell therapy customers, after receiving FDA Fast Track Designation, required less GMP reagent inventory in the near term, creating a temporary headwind. Additionally, the timing of a large OEM commercial supply order, which was pulled forward into the previous quarter, compounded the revenue shortfall.

• Large pharma resilience: Revenue from large pharmaceutical customers grew by low double digits, driven by robust investment in drug discovery and manufacturing. CEO Kelderman pointed to this segment as a “sustained strength,” helping to partially offset weaknesses elsewhere.

• Spatial Biology and Proteomic Analysis growth: The COMET spatial biology platform saw over 65% growth and a record backlog, while proteomic analysis instruments, especially the Ella platform for protein quantification, posted mid-single-digit growth. These areas are gaining traction in both academic and clinical research settings.

• Geographic and end-market trends: While the Americas declined, Europe and Asia (notably China) delivered growth, with China achieving its fourth consecutive quarter of positive organic revenue. Management credited strong demand from biopharma and contract research organizations (CROs) in China for this resilience.

Drivers of Future Performance

Management expects future performance to hinge on a recovery in biotech demand, continued strength from large pharma, and the scaling of high-growth platforms like spatial biology and proteomic analysis.

• Biotech spending lag: Management highlighted that while biotech funding rebounded in recent quarters, historical patterns suggest a two-to-three quarter lag before this translates into higher spending. CFO Hippel stated the team is “prudent about our Q4 forecast” and sees biotech as the biggest swing factor for growth acceleration.

• Strength in pharma and academia: Large pharmaceutical customers remain a bright spot, with continued double-digit growth expected. Academic markets are stabilizing, aided by improved NIH budgets and new grant activity. These trends support management’s expectation for normalization and gradual improvement across core product lines.

• Product and geographical momentum: High-growth areas, including the COMET spatial biology platform and Ella proteomic analysis instruments, are expected to drive incremental revenue. Ongoing momentum in China and product expansion in cell therapy and diagnostics are also positioned as key contributors, with management citing robust pipelines and customer engagement as positive signals.

Catalysts in Upcoming Quarters

In the next few quarters, the StockStory team will watch (1) whether emerging biotech order activity finally reflects the recent rebound in funding, (2) further traction and backlog expansion in the COMET and Ella platforms, and (3) continued stabilization in academic and international markets, particularly China. The normalization of order timing in cell therapy and OEM channels will also be key signposts for sustained revenue growth.

Bio-Techne currently trades at $47.31, down from $56.68 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.